Atypical hemolytic-uremic syndrome: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| Line 2: | Line 2: | ||
*One of the [[thrombotic microangiopathy|thrombotic microangiopathies]] |
*One of the [[thrombotic microangiopathy|thrombotic microangiopathies]] |
||
| − | * |
+ | *Different pathophysiology and treatment from [[hemolytic-uremic syndrome|typical hemolytic-uremic syndrome]] (after STEC diarrhea) and [[secondary hemolytic-uremic syndrome]] |
===Pathophysiology=== |
===Pathophysiology=== |
||
*Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity |
*Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity |
||
| + | *Mutations can occur anywhere in the complement pathway or, occasionally, in unrelated proteins |
||
| + | **Complement factor H (CFH), C3, factor B, factor I, CD46 |
||
| + | **Diacylglycerol kinase ε, plasminogen, factor XII (in the presence of anti-factor H autoantibodies), and thrombomodulin (CD141) |
||
==Diagnosis== |
==Diagnosis== |
||
Latest revision as of 09:50, 20 April 2023
Background
- One of the thrombotic microangiopathies
- Different pathophysiology and treatment from typical hemolytic-uremic syndrome (after STEC diarrhea) and secondary hemolytic-uremic syndrome
Pathophysiology
- Congenital defect leading to dysregulation of the alternative complement pathway, which leads to increased complement activity
- Mutations can occur anywhere in the complement pathway or, occasionally, in unrelated proteins
- Complement factor H (CFH), C3, factor B, factor I, CD46
- Diacylglycerol kinase ε, plasminogen, factor XII (in the presence of anti-factor H autoantibodies), and thrombomodulin (CD141)
Diagnosis
- Genetic mutation analysis of complement regulatory proteins (CFH, CFI, MCP, C3, CFB, THBD) and anti-CFH antibodies
Management
- Often unable to distinguish from TTP, so plasma exchange should be initiated promptly
- If no improvement on PLEX and there is significant renal involvement, consider:
- Eculizumab to inhibit C5 complement
- Ideally with full meningococcal vaccination beforehand
